The tumour vascular microenvironment supports tumorigenesis not only by supplying oxygen and diffusible nutrients but also by secreting soluble factors that promote tumorigenesis. Here we identify a feedforward mechanism in which endothelial cells (ECs), in response to tumour-derived mediators, release angiocrines driving aberrant vascularization and glioblastoma multiforme (GBM) progression through a hypoxia-independent induction of hypoxia-inducible factor (HIF)-1α. Phosphorylation of profilin-1 (Pfn-1) at Tyr 129 in ECs induces binding to the tumour suppressor protein von Hippel-Lindau (VHL), and prevents VHL-mediated degradation of prolyl-hydroxylated HIF-1α, culminating in HIF-1α accumulation even in normoxia. Elevated HIF-1α induces expression of multiple angiogenic factors, leading to vascular abnormality and tumour progression. In a genetic model of GBM, mice with an EC-specific defect in Pfn-1 phosphorylation exhibit reduced tumour angiogenesis, normalized vasculature and improved survival. Moreover, EC-specific Pfn-1 phosphorylation is associated with tumour aggressiveness in human glioma. These findings suggest that targeting Pfn-1 phosphorylation may offer a selective strategy for therapeutic intervention of malignant solid tumours.
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The tumour vascular microenvironment supports tumorigenesis not only by supplying oxygen and diffusible nutrients but also by secreting soluble factors that promote tumorigenesis. Here we identify a feedforward mechanism in which endothelial cells (ECs), in response to tumour-derived mediators, release angiocrines driving aberrant vascularization and glioblastoma multiforme (GBM) progression through a hypoxia-independent induction of hypoxia-inducible factor (HIF)-1α. Phosphorylation of profilin-1 (Pfn-1) at Tyr 129 in ECs induces binding to the tumour suppressor protein von Hippel-Lindau (VHL), and prevents VHL-mediated degradation of prolyl-hydroxylated HIF-1α, culminating in HIF-1α accumulation even in normoxia. Elevated HIF-1α induces expression of multiple angiogenic factors, leading to vascular abnormality and tumour progression. In a genetic model of GBM, mice with an EC-specific defect in Pfn-1 phosphorylation exhibit reduced tumour angiogenesis, normalized vasculature and improved survival. Moreover, EC-specific Pfn-1 phosphorylation is associated with tumour aggressiveness in human glioma. These findings suggest that targeting Pfn-1 phosphorylation may offer a selective strategy for therapeutic intervention of malignant solid tumours.
Tumours are now recognized as organ-like tissues of extreme complexity 1 . Stromal cells, extracellular matrix and soluble factors constitute the microenvironment that promotes tumour progression and metastasis, and induces therapeutic resistance [1] [2] [3] . Newly formed blood vessels deliver oxygen and nutrients to solid tumours and are crucial for their growth 4 . However, overgrown, topologically and structurally abnormal vasculature characterizes the microenvironment of most highly malignant tumours. These vessels are characterized by tortuous morphology and excessive sprouting, and are highly proliferative as well as leaky 5 . They create a host-hostile but tumour-friendly microenvironment that fuels tumour progression 6 . Therapies targeting vascular normalization recently have joined anti-angiogenesis as important strategies for reconditioning the tumour microenvironment and treating cancer 5, 7 . GBM, the grade IV glioma, is among the most malignant and highly vascularized tumours, with a present median survival of about 14 months in the United States 8, 9 . Most GBM tumours are refractory to conventional cytotoxic therapies, and during the past half-century there has been only limited improvement in patient treatment and prognosis 10 . GBM is distinguished by microvascular hyperplasia and extraordinary vascular abnormality of unknown etiology 8 . Anti-angiogenesis and vasculature-normalizing therapies, primarily targeting vascular endothelial growth factor (VEGF)-A and its receptors, have been developed and exploited in recent years. However, the therapeutic benefits have been small and transient, possibly owing to contributions of other angiogenic factors, acquired resistance to VEGF-antagonistic treatments, and harmful treatment side effects [11] [12] [13] . Development of strategies that target signalling molecules at points of convergence downstream of discrete angiogenic growth factor pathways may provide a solution for improving the clinical outcomes of patients with GBM.
We have recently shown that Tyr 129 phosphorylation of Pfn-1, a ubiquitously expressed actin-binding protein filament dynamics and increased vascular EC motility 15 . Here, we show an unexpected role for Pfn-1 phosphorylation in inducing expression of a plethora of angiogenic factors that drive vascular abnormality and GBM progression. Pfn-1 phosphorylation directs expression of endothelial angiocrines, significantly contributing to global expression of angiogenic factors in tumours. Inhibition of this EC-specific event reduces GBM progression in a genetic mouse model that recapitulates the main features of human disease, suggesting that Pfn-1 phosphorylation represents a selective therapeutic target for treatment of GBM and other malignant tumours.
RESULTS EC Pfn-1 phosphorylation at Tyr 129 drives GBM progression and aberrant vascularization
Tissue array-based, multiplex analysis of human breast, liver, brain, skin and prostate tumours revealed marked elevation of Tyr-129-phosphorylated Pfn-1 in multiple brain tumours types, with maximum expression in GBM ( Supplementary Fig. 1 ). To investigate the potential role of Pfn-1 phosphorylation in tumour progression, we took advantage of our conditional, EC-specific, phosphorylationdeficient Tie2-Cre;Pfn1 flox/flox:Y129F (Pfn1 Y129F ) knock-in mice 15 , and a genetically engineered, allogeneic mouse model of GBM that recapitulates the main features of human GBM (ref. 16) . A donor glioma was formed by stereotactic injection of DF-1 fibroblasts infected with retroviral RCAS-platelet-derived growth factor (PDGF)-B into the cortex of Nestin-tv-a Ink4a-Arf −/− Gli-luc donor mice (Fig. 1a) . The nestin promoter drives PDGF-B expression specifically in neural stem/progenitor cells. A single-cell suspension of the glioma was injected into the cortex of Pfn1 Y129F knock-in (that is, Tie2-Cre; Pfn1 flox/flox:Y129F ) or Pfn1 WT wild-type (that is, Pfn1 flox/flox:Y129F ) mice recipients. Consistent with previous studies, Pfn1
WT mice developed aggressive tumours exhibiting prominent vascularity with microvascular hyperplasia and extensive regions of necrosis (Fig. 1b) .
Pfn1
WT mice became moribund after about 30 days, and all were dead by 70 days. EC knock-in of Pfn1 Y129F increased median survival by about 7 days (P < 0.05; Fig. 1c ), nearly comparable to the 10-14-day increase in mouse survival by temozolomide, the present first-line standard of care for patient treatment of glioma 17, 18 . Interestingly, 3 of 14 Pfn1
Y129F mice survived for at least 90 days when the experiment was terminated (Fig. 1c) , further suggesting the significance of this microenvironment-dependent mechanism of tumour progression.
Tumours from Pfn1 Y129F knock-in mice have markedly reduced microvascular density (Fig. 1d) , and the vessels from Pfn1 WT mice exhibit morphological features typical of the vascular abnormality common in human GBM, that is, tortuous, granular and dilated with multi-layer wall thickening accompanied by extensive haemorrhage (Fig. 1e,f) . Remarkably, blood vessels in Pfn1 Y129F knock-in mice appear essentially 'normalized' as evidenced by non-tortuous, thin capillary vessels with less haemorrhage. Abnormal tumour vasculature is also characterized by insufficient coverage of nascent endothelium by pericytes, which hampers vessel maturation. Defective pericyte support and structural deformity of blood vessels are associated with poor functionality of the vasculature, leading to plasma leakage and spatially heterogeneous hypoxia 19 . Defective EC Pfn-1 phosphorylation substantially increased the extent of pericyte coverage on tumour blood vessels from 56.1 ± 8.2% to 87.3 ± 6.9% (mean ± s.e.m, n = 5 mice, P < 0.05 by two-tailed unpaired t-test, Fig. 1g ), inhibited leakage of intravenous fluorescein isothiocyanate (FITC)-dextran (as shown by decreased fluorescence intensity from 473 ± 117 to 145 ± 21, mean ± s.e.m, n = 5 mice, P < 0.05 by two-tailed unpaired t-test, Fig. 1h ), and reduced intra-tumoral hypoxia as determined by Hypoxyprobe-1 kit (as shown by decreased fluorescence intensity from 718 ± 104 to 329 ± 32, mean ± s.e.m, n = 5 mice, P < 0.05 by two-tailed unpaired t-test, Fig. 1i ). Together these results indicate an important contribution of Pfn-1 phosphorylation to vascular abnormality.
EC Pfn-1 phosphorylation at Tyr 129 contributes to aberrant tube formation, exuberant proliferation and monolayer hyperpermeability in vitro
To further investigate the EC-specific function of Pfn-1 phosphorylation, ECs isolated from Pfn1
WT and Pfn1 Y129F knock-in mice were incubated with human U251 glioma cell-conditioned medium (GCM) on Matrigel-coated dishes. Consistent with in vivo results, defective Pfn-1 phosphorylation of ECs substantially reduced vessel thickening and sprouting in vitro (Fig. 2a) . Similarly, GCMstimulated proliferation (Fig. 2b ) and monolayer permeability (Fig. 2c) were markedly reduced in Pfn1 Y129F ECs. These results suggest that tumour microenvironment-dependent Pfn-1 phosphorylation drives EC over-proliferation and vascular hyperpermeability, and contributes importantly to microvascular hyperplasia during GBM progression. We previously established a role for Pfn-1 phosphorylation at Tyr 129 in EC motility and vessel sprouting, consistent with its restricted localization at the cell leading edge during chemotaxis in response to VEGF-A (ref. 15) . Interestingly, GCM induced accumulation of Tyr-129-phosphorylated Pfn-1 to the perinuclear area as well as the cell leading edge in migrating ECs, in contrast to its restricted localization at cell protrusion sites in the absence of GCM (Fig. 2d) , possibly indicating an alternative function of Pfn-1 phosphorylation in the glioma microenvironment.
Pfn-1 phosphorylation at Tyr 129 is critical for expression of angiogenic growth factors in vitro and in vivo
We investigated the molecular mechanism underlying Pfn-1 phosphorylation-mediated vascular abnormality. Mouse GBM with defective EC-specific phosphorylation of Pfn-1 exhibited markedly reduced expression of the angiogenic growth factors VEGF-A and basic fibroblast growth factor (bFGF; Fig. 3a) . The result suggests that expression of Pfn-1 phosphorylation-mediated EC angiocrines contributes importantly to the burden of angiogenic growth factors in GBM. The specific role of ECs as a growth factor source was investigated by GCM stimulation of ECs isolated from mouse aorta. An angiogenesis-specific antibody array showed that GCM-induced EC expression of multiple growth factors and cytokines, including VEGF-A, VEGF-B, placenta growth factor (PlGF), heparin-binding epidermal growth factor-like growth factor (HB-EGF) and bFGF, was substantially higher in Tyr 129 Pfn-1 phosphorylation-competent ECs ( Fig. 3b and Supplementary Fig. 2 ). The requirement for Tyr 129 phosphorylation and GCM stimulation for enhanced expression of select targets was confirmed by immunoblot analysis (Fig. 3c) . Real-time PCR with reverse transcription (RT-PCR) revealed that regulation is primarily at the level of messenger RNA expression ( Fig. 3d) . These results suggest that the abundant vasculature in the GBM microenvironment expresses angiogenic factors at a high level in a Pfn-1 phosphorylation-dependent manner, contributing to vascular abnormality and tumour progression.
Pfn-1 phosphorylation-mediated expression of angiogenic factors requires HIF-1α
The expression of several phospho-Pfn-1-dependent factors, including VEGF-A, HB-EGF and bFGF, is induced by the hypoxia-inducible factor (HIF)-1α transcription factor in tumours 20, 21 . Consistent with these findings, GCM stimulated HIF-1α and -2α expression, the induction of both requiring Tyr 129 Pfn-1 phosphorylation in EC (Fig. 3e) . Remarkably, HIF-1α induction was observed even under normoxia, which ordinarily induces rapid ubiquitylation and degradation. Short interfering RNA (siRNA)-mediated knockdown showed that HIF-1α is essential for GCM-stimulated induction of growth factors ( Fig. 3f) , as well as for increased EC proliferation and permeability (Fig. 3g) . In contrast, HIF-2α knockdown did not appreciably inhibit growth factor expression (Fig. 3h) . Transcriptome-wide analysis of tumour-derived EC shows diminished expression of multiple HIF-1α-inducible genes in Pfn-1 phosphorylation-deficient mice (Supplementary Fig. 3 ). These results reveal an unexpected role for Pfn-1 phosphorylation in HIF-1α-mediated expression of angiogenic factors, which might contribute to EC proliferation and vascular hyperpermeability in the glioma microenvironment.
Tyr-129-phosphorylated Pfn-1 induces accumulation of Pro-hydroxylated HIF-1α by inhibiting VHL-mediated degradation
During normoxia, HIF-1α is subject to prolyl hydroxylation and consequent degradation mediated by the tumour suppressor protein VHL, thus driving low-level expression of HIF-1α in physiological conditions 22, 23 . The hypoxic tumour microenvironment suppresses prolyl hydroxylation of HIF-1α and VHL binding, thereby inducing HIF-1α accumulation 24, 25 . To explore the mechanism by which Pfn-1 phosphorylation induces HIF-1α in normoxia, we investigated the stimulus-dependent interactions of phospho-Pfn-1 with VHL and HIF-1α. Angiogenic growth factors expressed in human GBM, that is, VEGF-A, PlGF, bFGF and PDGF (refs 26,27) , stimulated phosphorylation of Pfn-1 and its interaction with VHL (Fig. 4a) ; particularly robust stimulation of both processes was observed with GCM. Pfn-1 bearing the Y129F mutation did not bind VHL in GCM-treated ECs, indicating a strict requirement for phosphorylation (Fig. 4b ). Co-immunoprecipitation confirmed the GCM-stimulated interaction between endogenous Pfn-1 and VHL (Fig. 4c) . Furthermore, co-localization of Tyr-129-phosphorylated Pfn-1 and VHL was detected, primarily in the perinuclear region of GBM-stimulated ECs (Fig. 4d) .
To investigate direct binding of Pfn-1 to VHL, the proteins were expressed and purified, and their interaction analysed by surface plasmon resonance (SPR) spectroscopy. Phosphorylated wild-type Pfn-1 (generated by in vitro incubation with lysate from GCMactivated cells or with purified Src kinase) exhibited greater affinity for VHL than the Y129F mutant ( Fig. 4e and Supplementary Fig. 4) . Furthermore, pre-incubation of VHL with lysate-treated Pfn-1 WT abrogated VHL binding to HIF-1α, whereas pre-incubation with Pfn-1 Y129F was ineffective, indicating that phosphorylation-dependent Pfn-1 binding to VHL prevents VHL binding to HIF-1α (Fig. 4f) . GCM: walls were quantified (mean ± s.e.m, n = 5 biologically independent samples per group, one representative experiment shown, and the experiment was repeated 3 times, two-tailed unpaired t-test). (d) Cells were treated with GCM, and cell proliferation determined by MTT assay (mean ± s.e.m, n = 5 biologically independent samples per group, one representative experiment shown, and the experiment was repeated 3 times). NS, not significant. Uncropped images of blots are shown in Supplementary Fig. 8 .
Pfn-1 also interacts with G-actin in a Tyr-129-phosphorylationdependent manner 15 . We found that G-actin competes with VHL for Pfn-1 binding, confirming the interaction of both partners at or near the same site ( Supplementary Fig. 5 ).
Phospho-Pfn-1 competition with HIF-1α for VHL binding might lead to constitutive expression of HIF-1α in its prolyl-hydroxylated form. Indeed, GCM treatment of ECs in normoxia induced HIF-1α expression to nearly the same extent as hypoxic treatment in the absence of GCM; however, only GCM induced accumulation of Pro-564-hydroxylated HIF-1α (Fig. 4g) . In the presence of nonphosphorylatable Pfn-1, HIF-1α was induced by hypoxia but not by GCM. Treatment of ECs with the proteasome inhibitor MG-132 induced robust accumulation of HIF-1α and Pro-564-hydroxylated HIF-1α in both Pfn-1 WT and Pfn-1 Y129F cells, suggesting that the Pfn-1 phosphorylation state does not influence prolyl hydroxylation of HIF-1α (Fig. 4h) . GCM did not stimulate Pfn-1 phosphorylation or HIF-1α expression in mouse fibroblasts or GBM cells, indicating EC specificity of the pathway (Fig. 4i) . Furthermore, knockdown of VHL substantially increased vessel thickening and sprouting on Matrigel and cell proliferation, and abolished the difference between Pfn-1 WT and Pfn-1 Y129F ECs, consistent with an important contribution of VHL to Pfn-1 phosphorylation-mediated vascular abnormality in glioma condition (Fig. 5a-d) .
To determine the in vivo role of this regulatory mechanism during GBM progression, Pro-564-hydroxylated HIF-1α was visualized in sections of mouse GBM tumours. Prolyl-hydroxylated HIF-1α was abundant in the tumour and co-localized almost exclusively with CD31 + blood vessels (Fig. 6a,b) ; tumours of Pfn-1 Y129F mice exhibited very low amounts of prolyl-hydroxylated HIF-1α and HIF-1α (Fig. 6a-c) . Similarly, human GBM specimens showed preferential co-localization of Pro-hydroxylated HIF-1α with EC, whereas total HIF-1α was distributed throughout the tissue (Fig. 6d) . Together, these results reveal a non-canonical, hypoxia-independent mechanism for HIF-1α induction, by which phospho-Pfn-1-Tyr-129 binds VHL and prevents VHL-mediated HIF-1α degradation, leading to accumulation of prolyl-hydroxylated HIF-1α in ECs in culture and in vivo, even in normoxia.
Phosphorylation of Pfn-1 at Tyr 129 is elevated in blood vessels of human GBM tumours, and is associated with glioma grade Pfn-1 phosphorylation was determined in human biopsy specimens during glioma progression to GBM. Elevated phospho-Pfn-1-Tyr-129 expression was observed in Grades III and IV glioma, but not in Grades I and II (Fig. 7a) . Quantitative immunofluorescence showed that Pfn-1 phosphorylation correlated with glioma grade in tumour regions and in ECs (Fig. 7b,c) . In all grades, phospho-Pfn-1-Tyr-129 expression was observed almost exclusively co-localizing with CD31 + blood vessels highly abundant in Grade IV (GBM) specimens (Fig. 7a,d) . Moreover, essentially all blood vessels in GBM tumour were associated with phospho-Pfn-1-Tyr-129.
Co-localization with CD144 (VE-cadherin)
+ vessels confirmed ECspecific Pfn-1 phosphorylation (Fig. 7e) . In contrast, phospho-AktSer-473, the critical regulatory product of PI(3)K activation, was more uniformly expressed, and co-localization with CD144 + blood vessels was minimal. Moreover, the distribution of total Pfn-1 was uniformly expressed throughout the tissue, and in healthy brain tissue (Fig. 7f) . These results further support EC-selective phosphorylation of Pfn-1 during GBM progression. Growth factor-stimulated induction of Pfn-1 phosphorylation in ECs, in tandem with the consequent increase in angiocrine expression, might constitute a feedforward loop, driving uncontrolled growth factor expression, aberrant vascularization, and consequent accelerated disease progression (Fig. 8) . Knockdown of HIF-1α inhibited GCM-induced Pfn-1 Tyr 129 phosphorylation, supporting the proposed feedforward mechanism of angiocrine production ( Supplementary Fig. 6 ).
Pfn-1 mRNA expression correlates with poor glioma patient survival
Consistent with the role of Pfn-1 phosphorylation in glioma progression, database analysis of GBM gene expression reveals elevated mRNA encoding Pfn-1, but not other actin-binding proteins including cofilin-1, formin, fascin and N-WASP ( Supplementary Fig. 7a,b) , suggesting a non-canonical function of Pfn-1 besides regulation of actin dynamics. Moreover, high Pfn-1 mRNA expression predicts poor glioma patient survival ( Supplementary Fig. 7c ), suggesting the possible role of Pfn-1 as a biomarker of glioma aggressiveness. However, the specific role of Pfn-1 phosphorylation in patient survival has not been investigated.
DISCUSSION
HIF-1α is a critically important transcription factor instrumental in regulating diverse cellular responses to hypoxia, inducing expression of glycolytic enzymes and multiple angiogenic growth factors that drive aberrant vascularization during tumorigenesis 6, 24, 25, 28 . HIF-1α is upregulated in most malignant tumours, primarily by hypoxiainduced protein stabilization 25 . Here we show a non-canonical, hypoxia-independent mechanism of HIF-1α induction in ECs, in which phosphorylation of Pfn-1 at Tyr 129 inhibits VHL-mediated HIF-1α degradation by direct, competitive inhibition of VHL binding to HIF-1α. In turn, elevated HIF-1α induces expression of multiple angiogenic factors, eventually leading to aberrant vascularization and GBM progression (Fig. 8) .
Phospho-Pfn-1 directs accumulation of HIF-1α even under normoxic conditions. Normoxic induction of HIF-1α by reactive oxygen species 29 , PLC/PKC (ref. 30 ) and succinate 31, 32 has been previously reported, and these agents inhibit protein hydroxylation thereby preventing recognition and degradation of HIF-1α by VHL. Likewise, human epidermal growth factor-like receptor 2 (HER2) induces HIF-1α expression in normoxia; however, the mechanism depends on increased synthesis of HIF-1α, not VHL-dependent degradation 33, 34 . HER2 expression correlates with the breast cancer progression and is an important diagnostic biomarker and therapeutic target for breast cancer, but is overexpressed in only 10-15% of GBM tumours [35] [36] [37] . Here we describe a distinct, phospho-Pfn-1-driven mechanism that prevents recognition of prolyl-hydroxylated HIF-1α by VHL, thereby facilitating accumulation of the modified protein in tumour ECs, even in a normoxic microenvironment.
The classic role of ECs is to provide physical structure that lines blood vessels; however, secretion of soluble factors by ECs robustly regulates post-injury tissue regeneration and tumorigenesis [38] [39] [40] [41] . Autocrine and paracrine effects of angiogenic growth factors, including VEGF and basic FGF, on ECs contribute importantly to vascular homeostasis and angiogenesis 21, [42] [43] [44] . Here, we show that expression of endothelial angiocrines driven by Pfn-1 phosphorylation significantly contributes to vascular abnormality and GBM progression. Endothelial angiocrines are a major source of angiogenic factors in GBM, probably owing to prominent vascularization of the tumour. Importantly, extensive and abnormal vasculature in malignant solid tumours has been linked to resistance to radiation and chemotherapy, and poor patient outcome 6 . In more than half of the GBM patients treated with anti-VEGF therapy, a transient response, therapeutic ineffectiveness and harmful side effects have been observed, possibly implicating other angiogenic factors, for example, placenta-derived, hepatocyte and fibroblast growth factors, in therapeutic resistance 12, 13, 45 . Therapeutic strategies specifically targeting signalling molecules at points of convergence downstream of these diverse angiogenic growth factor pathways might prove to be more effective with lesser adverse, off-target consequences. This concept is the basis of intensive investigation of inhibitors of the pro-angiogenic PI(3)K/Akt pathway as therapeutic targets for GBM (ref. 10) . We have previously shown that Tyr 129 phosphorylation of Pfn-1 is a principal component of an alternative pathway of sprouting angiogenesis that is independent of and complementary to the PI(3)K/Akt pathway 15 . Here, we show that Pfn-1 phosphorylation may present a critical regulatory node in EC expression of angiogenic factors, in addition to its direct stimulation of sprouting angiogenesis, both critical events in tumour vascularization. Moreover, Pfn-1 phosphorylation is preferentially induced in the blood vessels of GBM tumours, consistent with a role in regulation of EC-derived angiocrines, in contrast to the more uniform activation of PI(3)K/Akt in multiple cell types. Thus, inhibition of Pfn-1 phosphorylation may offer a selective therapeutic strategy for targeting expression of multiple angiogenic factors in tumours.
Pfn-1 is an actin-binding protein that regulates processes involved in cell propulsion including increasing G-actin availability and polymerization, as well as protease expression [46] [47] [48] . Our findings reveal an unconventional function of Pfn-1 in autocrine or paracrine signalling through HIF-1α induction and growth factor expression during GBM progression. Pfn-1 phosphorylation may have a major effect on HIF-1 stability rather than actin dynamics in glioma. Although Tie2 robustly drives EC gene expression, the Tie2 promoter is also activated in the myeloid lineage and thus Tie2-Cre-mediated knock-in of Pfn1 Y129F might reduce Pfn-1 phosphorylation in macrophages 49, 50 . Certainly tumour-associated macrophages have an important role in tumour vascularization and progression in glioma 50, 51 , but the contribution of macrophage Pfn-1 phosphorylation is not known.
In summary, Pfn-1 phosphorylation regulates endothelial angiocrine expression and drives aberrant vascularization and GBM progression through a hypoxia-independent HIF-1α induction mechanism. As a corollary, prevention of Pfn-1 phosphorylation might offer a selective target and strategy to inhibit endothelial angiocrine expression and normalize aberrant vasculature, recondition the microenvironment, and improve the therapeutic window for traditional chemotherapy, for example, treatment of GBM and possibly other solid malignant tumours.
METHODS
Methods and any associated references are available in the online version of the paper.
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Mouse model of GBM. Mouse GBM was induced as described previously 16, 52, 53 . In brief, Ntv-a/Ink4a-Arf −/− Gli-luc mice (6-8 week-old, n = 8 with equal numbers of males and females) were injected with chicken DF-1 fibroblasts (ATCC) that produce retrovirus encoding PDGF-B to induce GBM through RCAS/tv-a-mediated, gliaspecific gene transfer. Brain tumours were isolated and subjected to mechanical dissociation and papain digestion to obtain single-cell suspensions. Knock-in mice carrying a Pfn-1 Y129F mutation (Pfn-1 flox/flox:Y129F ) were generated in the C57Bl/6T background (Taconic), and bred with Tie2-Cre mice (Jax) expressing Cre recombinase (Tie2-Cre;Pfn1 flox/flox:Y129F ) for EC-specific expression. Pfn1 flox/flox:Y129F and Tie2-Cre;Pfn1 flox/flox:Y129F mice, 8-12 week old, n = 46 with equal numbers of males and females, were orthotopically, sterotactically injected with 5 × 10 5 tumour cells. Tumour formation was validated by whole-body bioluminescence using an IVIS 100 Imaging System (Xenogen) after retroorbital injection of luciferin (150 mg kg −1 , GoldBio). Post-injection survival was monitored for 90 days. Mice were euthanized when exhibiting severe GBM symptoms including domehead, haemiparesis, or more than 20% of body weight loss. All animal protocols were approved by the Animal Research Committee of the Cleveland Clinic, and all animals were housed in the Association for the Assessment and Accreditation of Laboratory Animal Careaccredited animal facility of the Cleveland Clinic. No statistical method was used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment.
Tumour vessel perfusion assay. Tumour-bearing mice were injected with FITClabelled dextran (100 mg kg −1 , Santa Cruz) through the tail vein. After 20 min, the mice were perfused through the left ventricle with PBS, and tumours were collected after euthanization. Cryosections were imaged with an HC upright fluorescence microscope (Leica).
Analysis of tumour hypoxia. Tumour hypoxia was determined with
Hypoxyprobe-1 Kit (Chemicon). Mice were intravenously injected with pimonidazole HCl (60 mg kg −1 ) through the tail vein. Tumour frozen sections were fixed with chilled acetone, probed with anti-pimonidazole adduct antibody (1:10, Chemicon), and then with Alexa Fluor 488-conjugated IgG (1:500, Invitrogen). Images were acquired with a DM5500B upright fluorescence microscope (Leica).
Preparation of glioma cell-conditioned medium. Human U251 and U87 glioma cells were cultured in DME/Ham's F-12 medium supplemented with 5% FBS. Cells at about 70% confluence were exposed to hypoxia (1% O 2 ) in a humidified air atmosphere at 37 • C for 24 h. Culture medium was centrifuged at 5, 000g for 30 min to remove cellular debris, and the supernatant was collected.
RNA isolation from tumour-derived ECs. Tumours were excised and minced to small pieces, followed by digestion with collagenase (Invitrogen, 17101-015, 1 mg ml −1 ) and dispase II (Invitrogen, 17105-041, 50 mg ml −1 ). Single-cell suspensions were incubated with biotinylated, anti-CD105 antibody (Miltenyi Biotech, 130-092-927, 10 µg ml −1 ) and streptavidin-conjugated magnetic beads (Miltenyi Biotech, 130-048-102, 1:50). Cells were collected by using a MACS separator (Miltenyi Biotech), and treated with glioma cell-conditioned medium (GCM). RNA was isolated using TRIzol reagent (Invitrogen).
Gene array analysis. Affymetrix mouse gene chip 2.0 ST and Expression Console software (Affymetrix) were used for microarray analysis. A comprehensive list of genes targeted by HIF-1α was compiled using the Molecular Signature database and literature 54, 55 . The HeatMap function in MATLAB was used to make a heatmap in which red represents values above the mean, black represents the mean, and green represents values below the mean of a row (gene) across all columns (samples). MS Access was used to filter upregulated and downregulated genes on the basis of the ratio of Tie2-Cre;Pfn1 flox/flox:Y129F to Pfn1 flox/flox:Y129F expression levels. A list of regulated genes were determined with a criterion of fold change < 0.66 and > 1.5 with P < 0.05, respectively.
Generation of Pfn-1 phospho-specific antibody. Polyclonal, phospho-specific antibody against the Pfn-1 phospho-Tyr-129 site was generated by injection of synthetic KLH-conjugated KKCpYEMASHLRR into rabbits (Open Biosystems) 15 .
Immunofluorescence. Human biopsy specimens from subjects with several tumour types including astrocytoma (US Biomax and BioChain), or healthy controls, were de-paraffinized and rehydrated, and subjected to antigen retrieval in Target Isolation and culture of ECs. Thoracic aortae were isolated from mice (2-weekold), and aortic rings in Matrigel-coated dishes were incubated in culture medium with 5% fetal bovine serum (FBS) for 5 days. After rinsing with PBS, the rings were removed, and the remaining cells were incubated with 2 U ml −1 dispase I (Sigma) for 20 min at 37 • C. After centrifugation at 500g for 10 min, the cell pellets were washed with PBS, and cells were cultured in DME/Ham's F-12 medium supplemented with 25 µg ml −1 EC growth supplement (Sigma), 10 U ml −1 heparin and 5% FBS at 37 • C in a humidified air atmosphere with 5% CO 2 . All cells were used between passages 3 and 6. Human microvascular ECs were maintained in Endothelial Cell Growth medium with SingleQuots supplements (Lonsa).
In vitro tube formation assay. Growth factor-reduced Matrigel (150 µl per chamber, BD Biosciences) was added to 8-chamber culture slides (BD Biosciences), incubated at 37 • C for 20 min, and washed with PBS. ECs were trypsinized and seeded on Matrigel at a density of 2 × 10 4 cells per chamber, allowed to attach for 4 h, and incubated in GCM or fresh medium with 5% FBS. Cells were imaged with a DM-IRB inverted microscope (Leica).
Cell proliferation assay. ECs were trypsinized and seeded on 96-well plates at a density of 7,500 cells per well, and allowed to attach for 4 h. Cells were cultured for up to 12 days in GCM or medium with 5% FBS, and washed with 100 µl fresh medium. Cells were incubated with methylthiazolyldiphenyl-tetrazolium bromide (MTT, 1 µM, Sigma) for 4 h at 37 • C. After adding 100 µl of 10% SDS in 10 mM HCl, absorbance was measured at 570 nm with a reference at 620 nm in a Spectramax 190 spectrophotometer (Molecular Devices).
In vitro vascular permeability assay. Mouse aortic ECs were seeded on Transwell inserts with a 0.4 µm pore filter (Costar), allowed to attach for 4 h, and cultured for 3 days to reach confluence. Cells were incubated with GCM or fresh medium with 5% FBS without phenol red. FITC-dextran (molecular mass 70,000 Da, Santa Cruz, SC-263323, 10 µg ml −1 ) was added to the upper chamber. After 6, 12, 24 and 48 h, the medium from the lower compartment was collected, and fluorescence was measured with an excitation wavelength of 485 nm and emission at 530 nm.
Angiogenesis antibody array analysis. ECs were incubated with GCM for 8 h, and lysed with NP-40 buffer (20 mM Tris at pH 7.5, 100 mM NaCl, 0.5% NP-40, 0.5 mM EDTA, 0.5 mM phenylmethylsulphonyl fluoride and 0.5% protease inhibitor cocktail, Sigma). Antibody-immobilized membranes of Mouse Angiogenesis Proteome Profiler Array (R&D, ARY015) were incubated with 300 µg of cell lysate, and immunoblotted according to manufacturer's instruction. Signal was analysed by densitometry using NIH ImageJ software.
Real-time RT-PCR analysis.
ECs were incubated with GCM for 8 h. mRNA was isolated with an Oligotex mRNA mini-kit (Qiagen), and subjected to real-time RT-PCR with an AgPath-ID One-Step RT-PCR kit (Ambion). Realtime PCR was performed in a 25-µl reaction volume using a StepOnePlus PCR system (Applied Biosystems), and TaqMan primers (Invitrogen): VEGF-A (Mm01281449_m1), VEGF-B (Mm00442102_m1), PlGF (Mm00435613_m1), HB-EGF (Mm00439306_m1), and GAPDH (Mm99999915_g1).
Plasmids, siRNAs and transfection. Pfn-1 CDS was amplified from a bovine cDNA pool (BioChain) and subcloned into pcDNA 3.1 (Invitrogen) with Flag-tag. Human Pfn-1 cDNA (OriGene) was subcloned into pECFP (Clontech) and pTriEx (Novagen) with His-tag. Pfn-1 mutants were generated by PCR using GeneTailor Site-Directed Mutagenesis System (Invitrogen). pcDNA-Pfn-1-Flag and pTriExPfn-1-His were used as a template to generate the Y129F mutation. Cloned plasmids were verified by sequencing. pCMV-HA-VHL was provided by H. Yang (Thomas Jefferson University). ECs at 40% confluence were transfected with plasmids using Fugene HD (Roche) in serum-free Opti-MEM medium (Invitrogen) for E n d o t h e l i n -1 NT5E  TIPARP  CCT6A  HMOX1  FAM162A  GPX3  DHX40  BNIP3  TMEM45A  IFI30  SYT17  IVNS1ABP  ZWILCH  PAK1  TIAM1  PDK1  PDK3  PGAM1  SLC25A13  SLC16A1  TMEFF1  CCNE1  DDIT4  NT5DC2  ABCG2  TSKU  POLA1  TPD52  ALDH1A2  CEP55  BBX  CASC5  DBF4  SAMD12  GBE1  VEGFA  PMAIP1  ERO1L  IGF2BP3  RORA  PLOD2  HIGD1A Fold change
Fold change > 1.5, P < 0.05
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